Tiny solutions for giant cardiac problems.
Health care nanotechnology research has "domesticated" molecular and cellular processes to serve our needs. This paper introduces current cardiovascular therapies for nanotechnologists unfamiliar with the field or current developments. Although early in its development, cell-based disease therapy capitalizes on existing biologic systems to implement nanoscale functionality. We propose that the most efficient development pathway for nanomedicine is to merge biomolecular and cellular techniques with the nanotechnology knowledge base.
Kong
David F
DF
Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA. kong0008@dcri.duke.edu
Goldschmidt-Clermont
Pascal J
PJ
D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy*; D036103:Nanotechnology; D015607:Stents
D020099:Coated Materials, Biocompatible